First Wave BioPharma Presents Research Demonstrating Benefits of Improved Adrulipase Drug Delivery Formulation at AAPS 2022 PharmSci 360
BOCA RATON, Fla., Oct. 10, 2022 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that research demonstrating key advantages of its improved adrulipase drug delivery formulation will be the subject of a poster presentation at AAPS 2022 PharmSci 360 on October 19 at 9:30 a.m., EDT. First Wave is developing adrulipase as a treatment for exocrine pancreatic insufficiency (EPI) associated with cystic fibrosis (CF) and chronic pancreatitis (CP). A Phase 2 clinical trial investigating the optimized adrulipase formulation is expected to initiate before year-end 2022.
Related news for (FWBI)
- First Wave BioPharma to Present at the DealFlow MicroCap Conference
- First Wave BioPharma CEO to Present at the Sequire Investor Summit 2024 in Puerto Rico
- First Wave BioPharma Chairman and CEO Issues Letter to Shareholders Highlighting Recent Accomplishments and Outlook for 2024
- First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.8 Million Gross Proceeds Priced
- First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program